About

Dr. Bing Yao is one of the co-founders, the Chief Executive Officer and Chairman of ArriVent. Dr. Yao is an accomplished executive and scientist with more than 20 years of experience in the biotechnology and pharmaceutical industry. Most recently, he served as Chairman and CEO of Viela Bio, which he co-founded in 2018. In 2021, Viela Bio was acquired by Horizon Therapeutics for $3.1 billion. Prior to his role at Viela, he served as Senior Vice President, Head of Respiratory, Inflammation, Autoimmunity iMED at MedImmune and as Senior Vice President, Head of Immuno-Oncology Franchise at AstraZeneca. During his tenure at MedImmune and AstraZenca, he played key leadership roles in the development and approval of multiple novel biologics for autoimmune, respiratory, and immune-oncology indications respectively. Prior to joining MedImmune, Dr. Yao led the project team leaders group for immunology, neurosciences, virology and metabolism for Genentech, and prior to that, served as Vice President and Head of Research for Tanox before it was acquired by Genentech in 2007. Earlier in his career, Dr. Yao held key roles at Aventis and Amgen. Dr. Yao has authored more than 50 peer-reviewed publications and holds over 20 patents and patent applications. Dr. Yao received his M.S. in Immunology from Anhui Medical University in Anhui, China and his Ph.D. in Microbiology and Immunology from the University of Iowa.

Dr. Stuart Lutzker is one of the co-founders, President and Head of Research & Development and a member of the board of directors of ArriVent. Dr. Lutzker has extensive drug development experience, having served as Vice President and Head of Oncology, Early Clinical Development at Genentech from 2009-2021. At Genentech, he led the early development of multiple now-approved oncology drugs including Kadcyla®, Polivy®, Venclexta®, Cotellic®, Lunsumio® and Tecentriq®. Previously, Dr. Lutzker was a medical oncologist and cancer researcher at the NCI Designated-Cancer Institute of New Jersey, where he split time between patient care and laboratory-based cancer research. He obtained a joint M.D. and Ph.D. in Biochemistry from Columbia University College of Physicians and Surgeons. Following his residency and fellowship in Internal Medicine and Medical Oncology at Yale-New Haven Hospital, Dr. Lutzker completed post-doctoral research training in the Department of Molecular Biology at Princeton University. Dr. Lutzker has also served as faculty for the AACR/ASCO Methods in Clinical Cancer Research Workshop in Vail, Colorado.

Robin LaChapelle is one of the co-founders and the Chief Operating Officer for ArriVent. Ms. LaChapelle is an accomplished executive with extensive experience in strategic planning, capital raising support, human resources assessment, executive compensation design and executive succession planning and coaching. Most recently, as Founder and Executive Director at RLT Consulting, she advised Biopharma Chief Executive Officers and board of directors from a number of companies including Viela Bio, Immunocore and Sanofi. Prior to establishing RLT Consulting, Ms. LaChapelle held various senior executive roles including Vice President of Human Resources for MedImmune and AstraZeneca, North America. In this role, she managed $1.2 billion in human resource spend for the company’s 14,000 employees. Additionally, Ms. LaChapelle served as Vice President, Global Total Rewards and Performance Management for Lockheed Martin, where she led compensation, benefits, retirement and performance management globally for 115,000 employees and partnered with the Board Compensation Committee. Before joining Lockheed, Ms. LaChapelle was Executive Vice President, Human Resources for Capital One Bank. Previously, Ms. LaChapelle also served as Senior Vice President of Marketing & Strategy at Bank of America, where she was responsible for all segments in the Commercial Bank with over $17 billion in revenue. Ms. LaChapelle has an M.A. In psychology from Loyola University Chicago, a B.A in Psychology from Indiana University and is a certified Coach.

Winston Kung is the Chief Financial Officer and Treasurer of ArriVent. From December 2017 to January 2024, Mr. Kung served as Chief Operating Officer and Chief Financial Officer at PMV Pharmaceuticals, a precision oncology company. From April 2013 to November 2017, Mr. Kung worked at Celgene Corporation, a global biopharmaceutical company, where he held multiple positions, including Vice President of Business Development and Global Alliances, and Chief Business Officer at Celgene Cellular Therapeutics, Inc. (a wholly-owned subsidiary of Celgene Corporation). At Celgene, Mr. Kung led the formation of a strategic long-range plan for the company, along with overseeing multiple transactions and a team that managed the company’s alliance portfolio of over 100 collaborations, equity investments and company integrations. Prior to working at Celgene, Mr. Kung worked at Citigroup Inc. from June 2010 to April 2013 in its Global Healthcare Investment Banking group and at Lehman Brothers (which was subsequently acquired by Barclays Capital Inc.) from May 2007 to June 2010 in its Global Mergers and Acquisitions Group. At Citigroup and Barclays, Mr. Kung worked on various transactions including public and private financings, mergers and acquisitions, spin-outs and other financial advisory engagements. From August 2004 to May 2007, Mr. Kung worked at Amgen Inc., a global biopharmaceutical company, as a co-founder of the Alliance Management group, and served as the deal lead on multiple acquisitions as part of the Corporate Development group. Mr. Kung also worked at Genentech, Inc., a biotechnology company (acquired by Roche Group in March 2009), from November 1999 to September 2002 as part of the Business and Corporate Development group. Since September 2022, Mr. Kung has served on the board of directors of Janux Therapeutics, Inc., a biopharmaceutical company. Mr. Kung previously served on the board of directors of Alliqua BioMedicial Inc., a provider of advanced wound care products, and GNS Healthcare, Inc., a private, healthcare artificial intelligence company. Mr. Kung received a B.A. in Biology and International Relations from Brown University and a M.B.A. from Harvard Business School.

Dr. Yang Wang is the Chief Technology Officer of ArriVent. Dr. Wang has more than 17 years of experience in biopharmaceutical process development and commercialization. Most recently, she served as Senior Vice President, Head of Chemistry, Manufacturing and Controls at Viela Bio, where she oversaw all aspects of process development, manufacturing, and supply of clinical and commercial products across the portfolio. Previously, Dr. Wang was Senior Director, Analytical Sciences at Biopharmaceutical Development, MedImmune, where she made key contributions to the BLA/MAA approval of three novel biologics. Dr. Wang also served as Director, Purification Process Sciences at MedImmune, and was responsible for leading the development of scalable downstream process for multiple complex novel molecules. Earlier in her career, she served as Chemistry Manufacturing and Controls Team Leader. Prior to joining MedImmune in 2009, Dr. Wang worked at Amgen and Pfizer in roles of increasing responsibility in process development, characterization, technology transfer, commercial manufacturing support and post-approval changes. She completed her Ph.D. in Biochemistry from University of Virginia, followed by Postdoctoral Research at Department of Cellular and Molecular Pharmacology at University of California, San Francisco.

Dr. Jim Kastenmayer is the General Counsel and Secretary for ArriVent. He is an accomplished biopharmaceutical general counsel and patent attorney with extensive strategic experience managing business-critical legal and compliance risks. Most recently, as General Counsel and Compliance Officer at Aeglea Biotherapeutics, he established their legal department along with the company’s legal and enterprise risk management framework and patent strategy. Prior to this role, Dr. Kastenmayer served as General Counsel and Senior Vice President at Viela Bio, where he built and led a successful legal department, provided strategic guidance and legal advice including advising the company in connection with the FDA approval and launch of Uplizna® and helped execute the company’s acquisition by Horizon Therapeutics in a deal worth more than $3 billion. Prior to Viela Bio, he served in roles of increasing responsibility at AstraZeneca, from May 2012 to December 2019, including global legal director, where he advised on commercialization and market access strategies, collaboration agreements and handled legal proceedings, as well as senior patent director, accountable for delivering global IP estates for small and large molecule therapies. Earlier in his career, Mr. Kastenmayer served as IP counsel at MedImmune, and as an associate at an IP boutique firm. Dr. Kastenmayer received a B.A. in Biology from the University of Virginia, a Ph.D. in Biochemistry and Cell and Molecular Biology from Michigan State University and a J.D. from Georgetown University Law Center.

Brent Rice serves as Chief Commercial Officer at ArriVent BioPharma, where he leads the company’s global commercial strategy and operations as it advances innovative oncology therapeutics toward global patient access.

Brent joined ArriVent following his tenure as Senior Vice President, Chief Commercial Officer & Managing Director US at Autolus Therapeutics, where he was instrumental in building and scaling the U.S. commercial organization as well as the successful launch of the companies first commercial product from October 2018 onward. Over a career spanning more than 25 years, Brent has held broad cross-functional leadership roles across biotech and pharmaceutical sales, marketing, operations, strategic planning, product launches, and reimbursement. He has a proven track record of negotiating multi-million-dollar agreements (ranging from $100M to $1B) that enhance patient access and drive commercial success.

Prior to Autolus, Brent shaped payer, access, and reimbursement strategies as Head of Managed Markets at Juno Therapeutics. Before that, he spent 18 years at Amgen, where he held key cross-functional roles supporting product lifecycle management, commercial partnerships, and franchise development.

Outside of biotech, Brent co-founded Building Employee Ownership, a financial services firm dedicated to optimizing employee participation in employer-sponsored ESPPs. He has also contributed as a board member of ACTION (Area Christians Taking Initiative On Needs), a nonprofit serving seniors, foster children, veterans, disabled individuals, and low-income families.

Brent earned his B.A. in Russian Studies from the University of California, Los Angeles and his MBA from the University of Denver.